Kenji Kita Selected Research

4-aminoimidazole

1/2019

Cancer stem-like properties and gefitinib resistance are dependent on purine synthetic metabolism mediated by the mitochondrial enzyme MTHFD2.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kenji Kita Research Topics

Disease

15	Neoplasms (Cancer) 01/2022 - 02/2012
12	Lung Neoplasms (Lung Cancer) 01/2022 - 02/2012
5	Neoplasm Metastasis (Metastasis) 01/2018 - 12/2011
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 07/2014
2	Colonic Neoplasms (Colon Cancer) 01/2022 - 01/2018
2	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 12/2017
2	Carcinogenesis 01/2022 - 01/2019
2	Brain Neoplasms (Brain Tumor) 01/2018 - 12/2017
2	Adenocarcinoma of Lung 12/2017 - 03/2015
2	Carcinoma (Carcinomatosis) 09/2017 - 03/2015
1	Microsatellite Instability 01/2022
1	Genomic Instability 01/2022
1	Adenoma (Adenomas) 01/2022
1	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2021
1	Atopic Dermatitis (Atopic Eczema) 08/2018
1	Peritoneal Neoplasms 12/2017
1	Stomach Neoplasms (Stomach Cancer) 12/2017
1	Pleural Effusion (Pleural Effusions) 09/2017
1	Malignant Mesothelioma 01/2015
1	Lymphoma (Lymphomas) 07/2014
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 12/2011

Drug/Important Bio-Agent (IBA)

7	Tyrosine Kinase InhibitorsIBA 01/2022 - 02/2012
6	Pharmaceutical PreparationsIBA 10/2019 - 02/2012
5	ErbB Receptors (EGF Receptor)IBA 07/2020 - 02/2012
5	Phosphotransferases (Kinase)IBA 01/2018 - 09/2012
4	Gefitinib (Iressa)FDA Link 01/2022 - 09/2012
4	osimertinibIBA 01/2022 - 12/2017
3	LigandsIBA 01/2022 - 07/2012
3	CrizotinibIBA 12/2017 - 07/2012
3	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 12/2017 - 02/2012
3	alectinibIBA 09/2017 - 07/2014
3	AntibodiesIBA 01/2015 - 12/2011
2	CateninsIBA 01/2022 - 01/2019
2	tyrosine receptor (receptor, tyrosine)IBA 01/2018 - 10/2017
2	entrectinibIBA 01/2018 - 12/2017
2	Proteins (Proteins, Gene)FDA Link 01/2018 - 07/2012
2	17- (dimethylaminoethylamino)- 17- demethoxygeldanamycinIBA 03/2016 - 07/2012
2	BIW-8962IBA 01/2015 - 12/2011
2	G(M2) Ganglioside (Ganglioside GM2)IBA 01/2015 - 12/2011
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 10/2012 - 07/2012
1	Biological ProductsIBA 01/2022
1	Frizzled ReceptorsIBA 01/2022
1	dacomitinibIBA 01/2022
1	Transcription Factors (Transcription Factor)IBA 01/2021
1	Glycogen Synthase Kinase 3IBA 07/2020
1	Glycogen Synthase (Synthase I)IBA 07/2020
1	EnzymesIBA 01/2019
1	4-aminoimidazoleIBA 01/2019
1	NucleotidesIBA 01/2019
1	AICA ribonucleotide (ZMP)IBA 01/2019
1	RibonucleotidesIBA 01/2019
1	purineIBA 01/2019
1	Phosphodiesterase 4 InhibitorsIBA 08/2018
1	methyl 4- (((3- (6,7- dimethoxy- 2- (methylamino)quinazolin- 4- yl)phenyl)amino)carbonyl)benzoateIBA 08/2018
1	TropomyosinIBA 01/2018
1	GSK 1363089IBA 01/2018
1	Type 1 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 1)IBA 10/2017
1	Diphosphonates (Bisphosphonates)IBA 03/2016
1	LuciferasesIBA 03/2015
1	GlycolipidsIBA 01/2015
1	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 07/2014
1	WZ4002IBA 10/2012
1	7-hydroxy-6-methoxyphthalide (MA-1)IBA 09/2012
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 09/2012
1	Neutralizing AntibodiesIBA 09/2012
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 09/2012
1	NVP-TAE684IBA 07/2012
1	Cetuximab (Erbitux)FDA Link 02/2012
1	Humanized Monoclonal AntibodiesIBA 12/2011

Therapy/Procedure

3	Therapeutics 01/2019 - 10/2012
1	Transplantation 01/2022